A phase 2 clinical trial has demonstrated that the combination of the anti-PD-1 monoclonal antibody tislelizumab and the tyrosine kinase inhibitor lenvatinib provides encouraging antitumor activity in patients with advanced fumarate hydratase-deficient renal cell carcinoma (FH-RCC). This rare, aggressive form of kidney cancer has historically lacked a well-established standard of care, leaving patients with limited therapeutic options. The study, which enrolled 20 patients, reported an objective response rate (ORR) of 95% among the participants, with 20% of patients achieving a complete response and 75% demonstrating a partial response. These findings, published in Nature Communications, suggest that the dual-therapy approach of targeting both tumor angiogenesis and immune checkpoint modulation may offer a potent first-line treatment pathway for a malignancy characterized by rapid progression and dismal prognosis.
Fumarate hydratase-deficient renal cell carcinoma is a rare malignancy primarily associated with hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome, caused by germline mutations in the FH gene, although it can also arise from somatic biallelic FH alterations. The tumorigenesis of this cancer is driven by metabolic rewiring within the tricarboxylic acid (TCA) cycle, leading to the abnormal accumulation of fumarate in tumor cells. Due to the aggressive biological behavior of this tumor type and its rarity, clinical trials have been challenging to conduct, and therapeutic management has often relied on historical data from trials investigating other RCC subtypes or broader non-clear cell RCC populations. The current study aimed to address this clinical gap by systematically evaluating a prospectively treated cohort in a single-arm, phase 2 clinical setting, registered under NCT05877820.
The study design required participants to have unresectable advanced or metastatic FH-RCC confirmed through morphological assessment and molecular testing for pathogenic or likely pathogenic FH mutations. The enrolled patients received concurrent treatment with lenvatinib at an initial dose of 20 mg orally once daily, paired with 200 mg of tislelizumab administered intravenously every three weeks. Treatment continued until patients experienced disease progression, unacceptable toxicity, or until they withdrew consent. The efficacy set included all 20 enrolled patients, with a median follow-up of 20.2 months. The investigators utilized Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 to conduct radiological evaluations every six weeks during the initial 24 weeks and every three months thereafter, providing a longitudinal look at treatment durability and patient outcomes.
Clinical results from the trial highlighted not only high response rates but also sustained clinical benefit. The disease control rate reached 100% (95% CI 83.2–100), and the clinical benefit rate, defined as disease control lasting for at least 24 weeks, was 85%. The median progression-free survival (PFS) was 20.7 months, and the median duration of response was 19.2 months. Notably, the median overall survival (OS) had not been reached by the time of data cutoff, with an estimated 2-year OS rate of 89.7% (95% CI 77.2–100). All patients exhibited measurable tumor shrinkage following the initiation of therapy, and no primary progression was observed in the cohort. The researchers observed that while the response rate was not statistically different between patients with FH germline mutations and those with somatic FH alterations, patients carrying germline mutations showed numerically favorable median PFS compared to the somatic subgroup, though the small number of patients in the latter group limited the power of formal statistical comparison.
The safety profile of the tislelizumab plus lenvatinib combination was consistent with reports from other ICI/TKI studies in renal cell carcinoma. All patients experienced at least one treatment-related adverse event (TRAE). Grade ≥3 TRAEs were reported in 45% of the study population, with the most common grade 3 events being hypertension and arthralgia. To manage these toxicities, the study protocol allowed for temporary dose interruptions or reductions of lenvatinib; 13 patients (65%) required these management strategies during the course of the trial. One patient permanently discontinued both agents due to a serious immune-related adverse event, specifically grade 3 pneumonitis. Despite the high frequency of any-grade TRAEs, the majority were manageable through standard interventions, supporting the clinical feasibility of this combination in the setting of advanced FH-RCC.
A critical component of this trial was the exploratory analysis of metabolic biomarkers. Given the unique metabolic rewiring in FH-deficient cells, the study tracked circulating levels of succinyl-adenosine and succinic-cysteine as potential surrogate markers for tumor burden. Using liquid chromatography-mass spectrometry, researchers monitored these plasma metabolites alongside routine radiological imaging. In 16 qualified patients, the dynamics of these biomarkers showed a coordinated change with the radiographic tumor burden determined by RECIST. In most responding patients, at least one of these two metabolic markers decreased by more than 80% within the first six weeks of treatment, often preceding imaging-confirmed response. Conversely, in patients who progressed, biomarker levels often demonstrated a rebound or rise that predated radiographic documentation of disease progression by several weeks in certain cases.
These findings suggest that serial monitoring of succinate-modifying metabolites may serve as a complementary tool to traditional imaging for the real-time assessment of treatment response and early warning of potential treatment failure. However, the researchers emphasized that the biomarker analysis was exploratory and limited by the small sample size. They were unable to calculate formal statistical metrics such as lead time, sensitivity, specificity, or false-positive/negative rates. Consequently, while the findings provide a robust proof-of-concept for metabolic biomarker-based monitoring in kidney cancer, they remain hypothesis-generating rather than practice-changing. The researchers noted that 20% of patients were excluded from the longitudinal analysis due to having baseline metabolic biomarker levels below the detection cutoff, likely reflecting a lower disease burden in those individuals that current assay sensitivity cannot fully capture.
The study also provided context by comparing its outcomes to other standard or emerging regimens. Historically, the AVATAR trial evaluated bevacizumab plus erlotinib in patients with HLRCC-associated papillary RCC, reporting a median PFS of 21.1 months. While the current study’s median PFS of 20.7 months is comparable, the rapid evolution of the RCC therapeutic landscape toward immunotherapy-based combinations makes the tislelizumab plus lenvatinib approach a pertinent alternative. Other combinations such as cabozantinib plus nivolumab or sintilimab plus axitinib have also shown encouraging antitumor efficacy in advanced FH-RCC. The researchers suggest that the distinct action mechanisms of these specific targeted therapies, particularly lenvatinib’s broader ability to modulate the tumor microenvironment and inhibit pathways such as FGFR, might contribute to the favorable clinical outcomes observed in this patient population.
Despite the promising results, the study authors identified several limitations inherent to rare-disease research. The single-arm, open-label design, combined with the lack of a comparator group or blinded independent central review, introduces potential biases in efficacy assessment. The small cohort size makes it difficult to draw definitive conclusions about the influence of mutation types—germline versus somatic—on the long-term efficacy or biomarker dynamics. The researchers acknowledged that the study could not provide a robust predictive model correlating these metabolic biomarker levels with radiographic findings and that the biomarkers should not be used in isolation but as an adjunct to standard clinical and radiographic assessment. These constraints underscore the complexity of conducting clinical trials in rare tumors where obtaining large, homogeneous cohorts is often a significant barrier.
Looking forward, the researchers emphasized the need for multicenter collaboration to accrue larger cohorts in future clinical trials. Such efforts should prioritize incorporating blinded independent central review to minimize potential assessment bias. Furthermore, prospective validation of the candidate metabolic biomarkers is essential, particularly with optimized, more sensitive assays and rigorous lead-time analysis. Whether other liquid biopsy biomarkers, such as circulating tumor DNA (ctDNA), could further guide clinical management in FH-RCC remains an area of active interest for future investigation. In the meantime, the current trial supports the use of tislelizumab plus lenvatinib as a viable first-line option for patients with advanced FH-RCC, demonstrating that targeted combination therapy combined with sophisticated biomarker monitoring could potentially refine clinical care for this challenging patient population.
Subject of Research: Phase 2 clinical trial assessing tislelizumab plus lenvatinib efficacy in advanced FH-deficient renal cell carcinoma.
Article Title: Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis
Article References: Kong, W., Xu, Y., Liu, G., Lv, W., Wang, Z., Cao, D., Jiao, F., Hu, J., Wu, X., Huang, J., Chen, Y., Zhai, W., Wu, X., Pan, J., Huang, Y., Wu, G., Zheng, L., Xue, W., & Zhang, J. (2026). Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis. Nature Communications, 17(1), Article 10591. https://doi.org/10.1038/s41467-026-77615-9
Image Credits: AI Generated
DOI: 10.1038/s41467-026-77615-9
Keywords: Renal Cell Carcinoma, Fumarate Hydratase Deficiency, Immunotherapy, Tislelizumab, Lenvatinib, Phase 2 Trial, Targeted Therapy, Succinyl-adenosine, Succinic-cysteine, Metabolic Biomarkers, Oncology, Kidney Cancer, Rare Diseases, Clinical Research, Immune Checkpoint Inhibitor, Tyrosine Kinase Inhibitor, Metastatic Cancer, HLRCC

